We are thrilled to announce that CytoNiche Biotech Co., Ltd. and OBiO Technology Co., Ltd. have forged a groundbreaking strategic alliance, unveiled on August 8, 2024, in Shanghai. This partnership is set to redefine the future of Cell and Gene Therapy (CGT) with the development of a cutting-edge intelligent 3D cell manufacturing platform.

[Transforming CGT with Innovative Technology]

Underpinned by the principles of synergy, integrity, and mutual benefit, this collaboration will focus on:

⚑ Developing advanced virus production processes using 3D FloTrix® technology

⚑ Creating a fully closed, automated technology platform for stem cells and exosomes

⚑ Leveraging 3D cell culture innovations for immunotherapy and regenerative medicine

This union aims to continuously push the boundaries of technology and accelerate advancements in the CGT industry.

[Pioneering Solutions for Advanced Therapies]

OBiO Tech brings unparalleled expertise with its 20 GMP-grade pipelines, offering comprehensive solutions across plasmids, retroviruses, lentiviruses, and diverse cell therapy products. Their robust process development and quality control systems ensure seamless support from preclinical research to commercial production.

CytoNiche Biotech, renowned for its state-of-the-art 3D FloTrix® automated systems, excels in large-scale, intelligent cell manufacturing. Our platforms are instrumental in producing stem cells, vaccines, and gene therapies, setting new standards in automated, standardized, and scalable cell drug production.

[A New Era of Collaboration and Innovation]

This strategic alliance is poised to elevate both partners’ technological capabilities and market presence. Together, we will drive the promotion and application of 3D FloTrix® technology, sparking significant advancements in the biopharmaceutical industry.

Dr. Jia Guodong, CEO of OBiO Tech, expressed enthusiasm about the partnership, emphasizing their commitment to technological innovation and the potential of the new platform to benefit researchers and pharmaceutical companies globally.

Dr. Liu Wei, Co-founder & CEO of CytoNiche Biotech, highlighted the strength of this alliance in expanding technical research and supporting biopharmaceutical companies, further energizing the CGT sector.

Stay tuned for more updates as CytoNiche and OBiO Tech embark on this exciting journey to reshape the future of cell manufacturing!

#StrategicPartnership #3DCellManufacturing #CGT #Innovation #CytoNicheBiotech #OBiOTech #Biopharma #CellTherapy #TechnologicalAdvancement

CytoNiche was established in 2018, led by Professor Yanan Du's research team from the School of Medicine at Tsinghua University, with Tsinghua University as a shareholder. The core technology originated from the transformation of scientific achievements at Tsinghua University and was recognized as a leading technology in "Science and Technology Innovation in China" by the China Association for Science and Technology. As a national-level high-tech enterprise, a national-level specialized and new technology "Little Giant" enterprise, a potential unicorn enterprise, it has also received key research and development special support from the Ministry of Science and Technology.

As an expert in high-quality three-dimensional cell manufacturing, CytoNiche provides a one-stop customized solution for cell scale-up based on 3D microcarriers. The company has built an original 3D cell smart manufacturing platform, achieving large-scale, automated, intelligent, and closed-cell drug and derivative production preparation. This helps global customers establish the most advanced cell drug production lines. After pioneering the production process pipeline for "billion-level" stem cells, the company is accelerating towards "hundred billion-level," dedicating efforts to empower the cell and gene therapy industry with 3D cell scale-up smart manufacturing technology to benefit more patients.